- ►diabetesjournals.org K Zhou, LA Donnelly, CH Kimber, PT Donnan, … - Diabetes, 2009 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS The Diabetes Audit and Research in Tayside Scotland
(DARTS) database includes prescribing and biochemistry information and clinical
phenotypes of all patients with diabetes within Tayside, Scotland, from ... Cited by 5 - Related articles - All 3 versions
ML Becker, LE Visser, RHN van Schaik, A … - The Pharmacogenomics Journal, 2009 - nature.com The organic cation transporter 1, encoded by the SLC22A1 gene, is responsible
for the uptake of the anti-hyperglycaemic drug, metformin, in the hepatocyte. We
assessed whether a genetic variation in the SLC22A1 gene is associated with ... Cited by 4 - Related articles - All 3 versions
- ►diabetesjournals.org ML Becker, LE Visser, RHN van Schaik, A … - Diabetes, 2009 - Am Diabetes Assoc OBJECTIVE— Metformin, an oral glucose-lowering drug, is taken up in
hepatocytes by the organic cation transporter (OCT) 1 and in renal epithelium by
OCT2. In these cells, the multidrug and toxin extrusion (MATE) 1 protein, ... Cited by 8 - Related articles - All 4 versions
AT Nies, H Koepsell, S Winter, O Burk, K … - Hepatology, 2009 - interscience.wiley.com An important function of hepatocytes is the biotransformation and elimination of
various drugs, many of which are organic cations and taken up by organic cation
transporters (OCTs) of the solute carrier (SLC) family 22. Because ... Cited by 3 - Related articles - All 2 versions
MV Tzvetkov, SV Vormfelde, D Balen, I Meineke, … - CliniCal pharmaCology & TherapeuTiCs, 2009 - crosbi.znanstvenici.hr Interindividual variations in the pharmacokinetics of drugs may be caused by
genetic variations in biotransformation and transmembrane transport.1–5
Metformin is a very important oral antidiabetic drug used in the treatment ... Cited by 2 - Related articles - View as HTML - All 8 versions
F Giorgino, P Gentili, T Bufacchi, N Visalli, M … - G It Diabetol Metab, 2009 - gidm.it Si discute da tempo su quale possa essere l'approccio tera- peutico più
corretto nei confronti del paziente con diabete di tipo 2 di recente insorgenza.
Certamente, l'approccio globa- le prevede che venga posta attenzione a vari ... Related articles - View as HTML - All 2 versions
MK Degorter, RB Kim - Hepatology (Baltimore, Md.), 2009 - ncbi.nlm.nih.gov 1: Hepatology. 2009 Aug 10;50(4):1014-1016. [Epub ahead of print]. Hepatic
drug transporters, old and new: Pharmacogenomics, drug ... Related articles - All 2 versions
[CITATION] Hepatic drug transporters, old and new: Pharmacogenomics, drug response, and clinical …
MK DeGorter, RB Kim - Hepatology, 2009 - Wiley Subscription Services, Inc., A Wiley Company … Related articles
- ►nih.gov Y Feng, G Mao, X Ren, H Xing, G Tang, Q Li, … - Diabetes Care, 2008 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A total of 1,268 type 2 diabetic patients whose
diabetes was diagnosed within the past 5 years and who had no recent
hypoglycemic treatment were enrolled from 23 hospitals in China. All of the ... Cited by 9 - Related articles - All 4 versions
MK CHOI, IS SONG - Drug Metabolism and Pharmacokinetics, 2008 - J-STAGE Inje University College of Medicine, #633-165 Gaegum-dong, Jin-gu, Busan
614-735, Korea. Tel. ＋8251-890-6412, Fax. ＋8251-893-1232, Email:
issong＠inje.ac.kr This study was supported by a grant of the Korea health ... Cited by 7 - Related articles - All 2 versions
